AU2001287632A1 - Use of matrix metalloprotease inhibitors for the treatment of cancer - Google Patents
Use of matrix metalloprotease inhibitors for the treatment of cancerInfo
- Publication number
- AU2001287632A1 AU2001287632A1 AU2001287632A AU8763201A AU2001287632A1 AU 2001287632 A1 AU2001287632 A1 AU 2001287632A1 AU 2001287632 A AU2001287632 A AU 2001287632A AU 8763201 A AU8763201 A AU 8763201A AU 2001287632 A1 AU2001287632 A1 AU 2001287632A1
- Authority
- AU
- Australia
- Prior art keywords
- mmp
- matrix
- active agent
- kinase
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 30
- 201000011510 cancer Diseases 0.000 title claims description 25
- 239000011159 matrix material Substances 0.000 title description 4
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims description 55
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 40
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 40
- 239000013543 active substance Substances 0.000 claims description 35
- 108091000080 Phosphotransferase Proteins 0.000 claims description 30
- 102000020233 phosphotransferase Human genes 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 230000019491 signal transduction Effects 0.000 claims description 24
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims description 17
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000003226 mitogen Substances 0.000 claims description 12
- 102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000012190 activator Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 101100457336 Homo sapiens MAPK12 gene Proteins 0.000 claims description 4
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 101150003567 Mapk12 gene Proteins 0.000 claims 1
- 101150105578 SAPK3 gene Proteins 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 84
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 108010044668 Activating Transcription Factor 1 Proteins 0.000 description 32
- 102100023026 Cyclic AMP-dependent transcription factor ATF-1 Human genes 0.000 description 32
- 239000003112 inhibitor Substances 0.000 description 27
- 230000004913 activation Effects 0.000 description 20
- 230000009545 invasion Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 230000001419 dependent effect Effects 0.000 description 15
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 14
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 description 13
- 102000001708 Protein Isoforms Human genes 0.000 description 13
- 108010029485 Protein Isoforms Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 102000005741 Metalloproteases Human genes 0.000 description 11
- 108010006035 Metalloproteases Proteins 0.000 description 11
- 230000006698 induction Effects 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000006552 constitutive activation Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 101000822645 Oryza sativa subsp. japonica Serine/threonine-protein kinase SAPK3 Proteins 0.000 description 7
- 230000009400 cancer invasion Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000007805 zymography Methods 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 101150060694 Mapk13 gene Proteins 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 101100202399 Oryza sativa subsp. japonica SAPK4 gene Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 102100023132 Transcription factor Jun Human genes 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100532679 Caenorhabditis elegans scc-1 gene Proteins 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 3
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 3
- 101100174184 Serratia marcescens fosA gene Proteins 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 101150078861 fos gene Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000013074 in-gel kinase assay Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 2
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 2
- 239000012826 P38 inhibitor Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- -1 SB 203580 (MW 377 Chemical class 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyridine Chemical class C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 101100191373 Arabidopsis thaliana PRK6 gene Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150032593 FOSL1 gene Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 101150096607 Fosl2 gene Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- 101150021395 JUND gene Proteins 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 1
- 102000046795 Mitogen-Activated Protein Kinase 3 Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101100457337 Mus musculus Mapk12 gene Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001621 anti-mitogenic effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 101150064107 fosB gene Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108700025907 jun Genes Proteins 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00114909 | 2000-07-17 | ||
| EP00114909A EP1174129A1 (fr) | 2000-07-17 | 2000-07-17 | Utilisation d'un inhibiteur de la métalloprotéase matricielle pour le traitement du cancer |
| PCT/EP2001/008234 WO2002005792A2 (fr) | 2000-07-17 | 2001-07-17 | Utilisation d'un principe actif pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001287632A1 true AU2001287632A1 (en) | 2002-01-30 |
Family
ID=8169222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001287632A Abandoned AU2001287632A1 (en) | 2000-07-17 | 2001-07-17 | Use of matrix metalloprotease inhibitors for the treatment of cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040067883A1 (fr) |
| EP (2) | EP1174129A1 (fr) |
| JP (1) | JP2004503583A (fr) |
| CN (1) | CN1458841A (fr) |
| AU (1) | AU2001287632A1 (fr) |
| CA (1) | CA2418146A1 (fr) |
| RU (1) | RU2003104511A (fr) |
| WO (1) | WO2002005792A2 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224013D0 (en) * | 2002-10-15 | 2002-11-27 | Oxford Glycosciences Uk Ltd | A protein involved in therapy |
| EP1627043A4 (fr) * | 2002-10-23 | 2006-10-11 | Exelixis Inc | Gene mapk7 en tant que modulateur de la morphogenese de ramification, et procedes d'utilisation |
| WO2006085828A1 (fr) * | 2005-02-11 | 2006-08-17 | Agency For Science, Technology And Research | Methodes de detection du carcinome hepatocellulaire |
| EP2403508B1 (fr) * | 2009-03-06 | 2015-10-28 | Université Paris Descartes | Methode pour le traitment du cancer par un milieu de culture conditionnés derivée de fibroblastes de gencives |
| WO2014100779A1 (fr) | 2012-12-21 | 2014-06-26 | Advanced Cell Technology, Inc. | Procédés de production de plaquettes à partir de cellules souches pluripotentes, et compositions associées |
| US20170038382A1 (en) * | 2014-01-24 | 2017-02-09 | Ntercept, Llc | Methods and compositions for immune dis-inhibition |
| AU2015327928A1 (en) | 2014-10-03 | 2017-05-04 | Nanotics, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
| EA201890391A1 (ru) | 2015-07-29 | 2018-08-31 | НАНОТИКС, ЭлЭлСи | Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы |
| EP3565604A4 (fr) | 2017-01-04 | 2020-09-09 | Nanotics, LLC | Procédés d'assemblage de particules éliminatrices |
| EP3502279A1 (fr) * | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Évaluation de l'activité de la voie de signalisation cellulaire mapk-ap 1 faisant appel à une modélisation mathématique de l'expression du gène cible |
| CN109528720B (zh) * | 2019-01-08 | 2021-03-30 | 浙江大学 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2877509B2 (ja) * | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| CA2267656A1 (fr) * | 1996-10-09 | 1998-04-16 | Medical Research Council | Proteine kinases activees par les mitogenes, polypeptides, polynucleotides et leur utilisation |
| EP1023313A1 (fr) * | 1997-05-28 | 2000-08-02 | Daniel A. Mercola | Inhibition de la voie de la proteine kinase activee par le stress et sensibilisation des cellules aux therapies anticancereuses |
| ID24957A (id) * | 1998-02-04 | 2000-08-31 | Novartis Ag | Turunan sulfonilamino yang menginhibisi metaloproteinase penurun matriks |
| FI980604A0 (fi) * | 1998-03-18 | 1998-03-18 | Univ Helsinki Licensing | Nya matrismetalloproteinasinhibitorer och -regulatorer |
| US6277061B1 (en) * | 1998-03-31 | 2001-08-21 | The Research Foundation Of State University Of New York | Method of inhibiting membrane-type matrix metalloproteinase |
| GB9809869D0 (en) * | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
| JP4748338B2 (ja) * | 1998-09-11 | 2011-08-17 | 味の素株式会社 | ベンゼン誘導体及びその医薬用途 |
| GB9902696D0 (en) * | 1999-02-09 | 1999-03-31 | Medical Res Council | Screening methods |
| EP1229925A2 (fr) * | 1999-11-19 | 2002-08-14 | Axxima Pharmaceuticals Aktiengesellschaft | Inhibiteurs de maladies gastro-intestinales induites par helicobacter pilori |
-
2000
- 2000-07-17 EP EP00114909A patent/EP1174129A1/fr not_active Withdrawn
-
2001
- 2001-07-17 US US10/332,903 patent/US20040067883A1/en not_active Abandoned
- 2001-07-17 JP JP2002511725A patent/JP2004503583A/ja active Pending
- 2001-07-17 WO PCT/EP2001/008234 patent/WO2002005792A2/fr not_active Application Discontinuation
- 2001-07-17 EP EP01967193A patent/EP1301182A2/fr not_active Withdrawn
- 2001-07-17 AU AU2001287632A patent/AU2001287632A1/en not_active Abandoned
- 2001-07-17 CN CN01815690A patent/CN1458841A/zh active Pending
- 2001-07-17 CA CA002418146A patent/CA2418146A1/fr not_active Abandoned
- 2001-07-17 RU RU2003104511/15A patent/RU2003104511A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2003104511A (ru) | 2004-08-20 |
| WO2002005792A2 (fr) | 2002-01-24 |
| US20040067883A1 (en) | 2004-04-08 |
| WO2002005792A9 (fr) | 2002-09-19 |
| JP2004503583A (ja) | 2004-02-05 |
| EP1301182A2 (fr) | 2003-04-16 |
| WO2002005792A3 (fr) | 2002-05-30 |
| CA2418146A1 (fr) | 2002-01-24 |
| EP1174129A1 (fr) | 2002-01-23 |
| CN1458841A (zh) | 2003-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simon et al. | The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation | |
| Lennartsson et al. | Stem cell factor receptor/c-Kit: from basic science to clinical implications | |
| Endo et al. | Insight into the role of Wnt5a-induced signaling in normal and cancer cells | |
| Krygowska et al. | PI3K: a crucial piece in the RAS signaling puzzle | |
| Tuckermann et al. | The DNA binding-independent function of the glucocorticoid receptor mediates repression of Ap-1–dependent genes in skin | |
| Sridhar et al. | Protein kinases as therapeutic targets | |
| Long et al. | Regulation of the M r 72,000 type IV collagenase by the type I insulin-like growth factor receptor | |
| Cuenda et al. | p38 MAP-kinases pathway regulation, function and role in human diseases | |
| Berra et al. | MAP kinases and hypoxia in the control of VEGF expression | |
| Halder et al. | Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosis | |
| Hauck et al. | Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells | |
| Silva et al. | The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38α MAPK isoform | |
| Wen et al. | TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells | |
| Anderegg et al. | ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells | |
| Clevenger | Role of prolactin/prolactin receptor signaling in human breast cancer | |
| JP2014532647A (ja) | 消化管間質腫瘍を治療する方法 | |
| US20040067883A1 (en) | Use of matrix metalloprotease inhibitors for the treatment of cancer | |
| Meng et al. | High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) | |
| US9931342B2 (en) | Compositions and methods for the treatment of cancer | |
| Ciampolillo et al. | The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer | |
| Lakka et al. | Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades | |
| WO2016198698A2 (fr) | Inhibiteurs de p38 pour le traitement et la prophylaxie du cancer du foie | |
| Tennis et al. | Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1 | |
| Matsubara et al. | Transactivation of EGF receptor induced by angiotensin II regulates fibronectin and TGF-β gene expression via transcriptional and post-transcriptional mechanisms | |
| US8633161B2 (en) | Therapeutic agents for the treatment of leukemia |